Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C. | ClinicalTrials HQ

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity	Body Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorder	Recruiting	Phase 3	2026-10-08		NCT07794579
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)	Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, heart disorder, kidney disorder, kidney failure, nervous system disorder, stroke disorder, urinary system disorder, vascular disorder	Recruiting	Phase 3	2026-10-08		NCT07241390
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder	Active, not recruiting	Phase 3	2026-10-08		NCT06292013
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder	depressive disorder, major depressive disorder, mood disorder, psychiatric disorder	Recruiting	Phase 3	2026-10-07		NCT07775300
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition	Active, not recruiting	Phase 3	2026-10-07		NCT05556512
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	cardiovascular disorder, heart disorder, heart failure	Recruiting	Phase 3	2026-10-01		NCT06935370
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder	Recruiting	Phase 3	2026-09-30		NCT07064473
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)	Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder	Recruiting	Phase 3	2026-09-24		NCT07157774
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis	Active, not recruiting	Phase 3	2026-04-20		NCT03519945